AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19447808 — intervention group
Group type: COMPARATOR
Intervention: Low RVP (RVP 0%, n = 189)
Number of subjects: 213
Study 16855141 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolactin response to hypoglycemia in SSc patients
Number of subjects: 2
Study 16855141 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolactin response to hypoglycemia in PsA patients
Number of subjects: 2
Study 16855141 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone response to hypoglycemia in SSc and PsA patients
Number of subjects: 2
Study 16855141 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone response to hypoglycemia in healthy controls
Number of subjects: 2
Study 15087264 — intervention group
Group type: EXPERIMENTAL
Intervention: High procyanidin chocolate (200 mg of flavanols and related procyanidins)
Number of subjects: 18
Study 15087264 — intervention group
Group type: EXPERIMENTAL
Intervention: Low procyanidin chocolate (less than 10 mg of polyphenols)
Number of subjects: 18
Study 10958263 — intervention group
Group type: EXPERIMENTAL
Intervention: New serotonergic-noradrenergic antidepressant
Number of subjects: 216
Study 9295890 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic substances during acute myocardial infarction
Number of subjects: 175
Study 7956958 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned chronic injection sclerotherapy (at three weekly intervals)
Number of subjects: 40
Study 7956958 — intervention group
Group type: COMPARATOR
Intervention: Demand injection sclerotherapy (after variceal bleeds only)
Number of subjects: 40
Study 3234187 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5% and placebo
Number of subjects: 40
Study 3234187 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 1% and placebo
Number of subjects: 40
Study 3234187 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5% and Indomethacin 1%
Number of subjects: 40
Study 3234187 — intervention group
Group type: COMPARATOR
Intervention: Placebo and placebo
Number of subjects: 40
Study 28956620 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (CBT + sertraline)
Number of subjects: 488
Study 28956620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 488
Study 28956620 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 488
Study 28956620 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 488
Study 28582570 — intervention group
Group type: EXPERIMENTAL
Intervention: Filorexant 10 mg
Number of subjects: 129
Study 28582570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 25589680 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week pre quit bupropion
Number of subjects: 95
Study 25589680 — intervention group
Group type: COMPARATOR
Intervention: 1-week pre quit bupropion (standard run-in)
Number of subjects: 95
Study 24660606 — intervention group
Group type: EXPERIMENTAL
Intervention: Pricking-bloodletting cupping at Dazhui (GV 14) under acupuncture anesthesia at Hegu (LI 4) and Quchi (LI 11)
Number of subjects: 38
Study 24660606 — intervention group
Group type: COMPARATOR
Intervention: Pricking-bloodletting cupping at Dazhui (GV 14)
Number of subjects: 38
Study 21533995 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa 100 mg three times on day 1
Number of subjects: 16
Study 21533995 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa 100 mg with COMT-inhibitor entacapone (EN) on day 2
Number of subjects: 16
Study 21533995 — intervention group
Group type: COMPARATOR
Intervention: Comparison between day 1 and day 2
Number of subjects: 16
Study 19706352 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninterrupted group
Number of subjects: 312
Study 16573871 — intervention group
Group type: EXPERIMENTAL
Intervention: BBC prison study
Number of subjects: 0
Study 14627174 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort Turbuhaler) 160/4.5 mg, two inhalations b.i.d.
Number of subjects: 320
Study 14627174 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort Turbuhaler)
Number of subjects: 320
Study 14627174 — intervention group
Group type: COMPARATOR
Intervention: Budesonide plus formoterol separate inhalers
Number of subjects: 320
Study 10807021 — intervention group
Group type: EXPERIMENTAL
Intervention: Case Management (CM)
Number of subjects: 302
Study 10807021 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 302
Study 9356109 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% N2O in oxygen for 10 min
Number of subjects: 20
Study 9356109 — intervention group
Group type: COMPARATOR
Intervention: 50% nitrogen (control group)
Number of subjects: 20
Study 9356109 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O group
Number of subjects: 20
Study 9356109 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 8382424 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal application of yoghurt
Number of subjects: 32
Study 2859077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamphetamine sulphate tablets 10 mg
Number of subjects: 20
Study 2859077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamphetamine sulphate tablets 30 mg
Number of subjects: 20
Study 2859077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexedrine Spansules 10 mg
Number of subjects: 20
Study 2859077 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol 4 mg
Number of subjects: 20
Study 2859077 — intervention group
Group type: EXPERIMENTAL
Intervention: Fencamfamin hydrochloride 60 mg
Number of subjects: 20
Study 29540571 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance-linked incentives (Rs30 or $0.50 of phone talk time)
Number of subjects: 608
Study 29540571 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone reminders
Number of subjects: 608
Study 29540571 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 608
Study 27550361 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5847 at 500 mg twice daily
Number of subjects: 15
Study 27550361 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5847 at 500 mg once daily
Number of subjects: 15
Study 27550361 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5847 at 1,200 mg once daily
Number of subjects: 15
Study 27550361 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5847 at 800 mg twice daily
Number of subjects: 15
Study 27550361 — intervention group
Group type: COMPARATOR
Intervention: Combination of isoniazid, rifampin, ethambutol, and pyrazinamide (standard chemotherapy)
Number of subjects: 15
Study 24907877 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml 0.5% bupivacaine (Group B)
Number of subjects: 60
Study 24907877 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml 0.5% levobupivacaine (Group L)
Number of subjects: 60
Study 24907877 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups (Group B and Group L)
Number of subjects: 60
Study 23337198 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (90% ventilatory threshold)
Number of subjects: 20
Study 23337198 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 20
Study 21962098 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal carbon dioxide (10 mL/s for 10 seconds per nostril)
Number of subjects: 348
Study 21962098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study 18405155 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion at 'heat sensitive points', treated once a day for 10 days.
Number of subjects: 120
Study 18405155 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine Hydrochloride, 10 mg orally, once daily for 10 days.
Number of subjects: 120
Study 16878213 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal dentifrice
Number of subjects: 48
Study 16878213 — intervention group
Group type: COMPARATOR
Intervention: Dentifrice with triclosan and fluoride (positive control)
Number of subjects: 48
Study 12514658 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril (30-60 mg/day)
Number of subjects: 1024
Study 12514658 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril (5-10 mg/day)
Number of subjects: 1024
Study 10462245 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted influenza vaccine (FLUAD)
Number of subjects: 0
Study 10462245 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted subunit vaccine
Number of subjects: 0
Study 8698756 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (150 mg/day) for seven days before operation
Number of subjects: 30
Study 8698756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2016621 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CT) alone (CYC/ADR)
Number of subjects: 62
Study 2016621 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with concurrent radiation therapy (CT/RT)
Number of subjects: 62
Study 2016621 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CT and CT/RT groups
Number of subjects: 62
Study 2016621 — intervention group
Group type: EXPERIMENTAL
Intervention: CT/RT arm
Number of subjects: 62
Study 6992677 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim (100 mg)
Number of subjects: 60
Study 6992677 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin macrocrystals (100 mg)
Number of subjects: 60
Study 6992677 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (40 mg/200 mg)
Number of subjects: 60
Study 6992677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31868819 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined drug and wedge-shaped pillow (WSP) treatment for 3 months after 2 weeks of drug only and drug plus WSP sequences.
Number of subjects: 14
Study 31868819 — intervention group
Group type: COMPARATOR
Intervention: Drug only sequence for 2 weeks.
Number of subjects: 14
Study 31868819 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined drug and WSP treatment after 3 months.
Number of subjects: 14
Study 30661716 — intervention group
Group type: EXPERIMENTAL
Intervention: Minced skin grafting applied over the study area
Number of subjects: 30
Study 30661716 — intervention group
Group type: COMPARATOR
Intervention: Control area (no minced skin grafting)
Number of subjects: 30
Study 30661716 — intervention group
Group type: EXPERIMENTAL
Intervention: Minced skin grafting
Number of subjects: 30
Study 28671507 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (CLM) 500 mg every 12 hours for 3 days with one-stage full-mouth ultrasonic debridement (FMUD)
Number of subjects: 40
Study 28671507 — intervention group
Group type: COMPARATOR
Intervention: Placebo with one-stage full-mouth ultrasonic debridement (FMUD)
Number of subjects: 40
Study 25911394 — intervention group
Group type: COMPARATOR
Intervention: Aperture fixation using femoral and tibial joint-line fixation with a femoral cannulated interference screw and a tibial cannulated interference retrograde screw
Number of subjects: 64
Study 25911394 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspensory fixation using femoral and tibial cortical buttons
Number of subjects: 64
Study 25911394 — intervention group
Group type: COMPARATOR
Intervention: Aperture fixation
Number of subjects: 64
Study 25911394 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspensory fixation
Number of subjects: 64
Study 24235064 — intervention group
Group type: COMPARATOR
Intervention: 4-week supervised exercise program
Number of subjects: 22
Study 24235064 — intervention group
Group type: COMPARATOR
Intervention: 8-week supervised exercise program
Number of subjects: 22
Study 21349913 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrostimulation (NMES) for 6 weeks, delivered to quadriceps and hamstring muscles (35 Hz)
Number of subjects: 15
Study 21349913 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrostimulation (NMES)
Number of subjects: 15
Study 21349913 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 15
Study 19918852 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 472
Study 19918852 — intervention group
Group type: COMPARATOR
Intervention: Open resection
Number of subjects: 472
Study 17628232 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0
Study 17628232 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab or Certolizumab
Number of subjects: 0
Study 17628232 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-integrin α4 therapies
Number of subjects: 0
Study 17628232 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunostimulating therapy (granulocyte-monocyte colony-stimulating factor)
Number of subjects: 0
Study 17628232 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapies
Number of subjects: 0
Study 15149889 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 24
Study 15149889 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 80 mg/day (Control)
Number of subjects: 24
Study 15149889 — intervention group
Group type: COMPARATOR
Intervention: Normotensive subjects (Control)
Number of subjects: 24
Study 11298390 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radio frequency electromagnetic fields (900 MHz, pulsed at 217 Hz, average power flux density 1 W/m2)
Number of subjects: 8
Study 11298390 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 8
Study 9204086 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel
Number of subjects: 42
Study 9204086 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin 0.025% gel
Number of subjects: 42
Study 9204086 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene aqueous 0.03% and 0.1% gels
Number of subjects: 42
Study 9204086 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene alcoholic 0.03% and 0.1% gels
Number of subjects: 42
Study 9204086 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene gel vehicles or patch alone
Number of subjects: 42
Study 9204086 — intervention group
Group type: COMPARATOR
Intervention: TEWL measurement at tretinoin site
Number of subjects: 42
Study 9204086 — intervention group
Group type: EXPERIMENTAL
Intervention: TEWL measurement at adapalene sites
Number of subjects: 42
Study 7962382 — intervention group
Group type: EXPERIMENTAL
Intervention: In-vitro fertilization (IVF)
Number of subjects: 99
Study 7962382 — intervention group
Group type: COMPARATOR
Intervention: Ovarian stimulation without IVF
Number of subjects: 99
Study 7962382 — intervention group
Group type: COMPARATOR
Intervention: Natural conception
Number of subjects: 99
Study 7962382 — intervention group
Group type: EXPERIMENTAL
Intervention: Oocyte donation
Number of subjects: 99
Study 3630816 — intervention group
Group type: EXPERIMENTAL
Intervention: MLCu250 + 0.3 mg estradiol releasing about 1 microgram per day
Number of subjects: 90
Study 3630816 — intervention group
Group type: EXPERIMENTAL
Intervention: MLCu250 + 1.0 mg estradiol releasing about 3 micrograms per day
Number of subjects: 90
Study 3630816 — intervention group
Group type: COMPARATOR
Intervention: MLCu250
Number of subjects: 90
Study 29147969 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary phospholipids (PLs) at 8.5 g kg‐1
Number of subjects: 0
Study 29147969 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary phospholipids (PLs) at increasing levels (8.5 to 41.5 g kg‐1)
Number of subjects: 0
Study 29147969 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary phospholipids (PLs) at increasing levels
Number of subjects: 0
Study 29147969 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary phospholipids (PLs)
Number of subjects: 0
Study 27648684 — intervention group
Group type: COMPARATOR
Intervention: 20 μg Engerix-B® with 0, 1, 6 month intervals
Number of subjects: 1169
Study 27648684 — intervention group
Group type: COMPARATOR
Intervention: 20 μg Kangtai hepatitis B vaccine with 0, 1, 6 month intervals
Number of subjects: 1169
Study 27648684 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 μg Kangtai hepatitis B vaccine with 0, 2 month intervals
Number of subjects: 1169
Study 27648684 — intervention group
Group type: COMPARATOR
Intervention: 20 μg Huabei hepatitis B vaccine with 0, 1, 6 month intervals
Number of subjects: 1169
Study 24742322 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief manual-guided motivational intervention with a phone booster at 10 days
Number of subjects: 600
Study 24742322 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 600
Study 24742322 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief manual-guided motivational intervention
Number of subjects: 600
Study 23153657 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (BEV)
Number of subjects: 44
Study 23153657 — intervention group
Group type: COMPARATOR
Intervention: Grid laser photocoagulation (GLP)
Number of subjects: 44
Study 23153657 — intervention group
Group type: COMPARATOR
Intervention: Switching therapy for non-responders
Number of subjects: 44
Study 20805433 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 241
Study 20805433 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 241
Study 18556343 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin injections
Number of subjects: 0
Study 18556343 — intervention group
Group type: COMPARATOR
Intervention: Oral antidiabetes drugs (OADs)
Number of subjects: 0
Study 15739544 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin treatment (40 mg subcutaneously once daily)
Number of subjects: 170
Study 15739544 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 170
Study 12952844 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe OSA patients
Number of subjects: 20
Study 12952844 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study 12952844 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe OSA female patients
Number of subjects: 20
Study 12952844 — intervention group
Group type: COMPARATOR
Intervention: Control female subjects
Number of subjects: 20
Study 12952844 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild OSA patients
Number of subjects: 20
Study 10912887 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific inspiratory muscle training (SIMT)
Number of subjects: 20
Study 10912887 — intervention group
Group type: COMPARATOR
Intervention: Sham training (Control)
Number of subjects: 20
Study 8866698 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPT
Number of subjects: 17
Study 8866698 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine (active control)
Number of subjects: 17
Study 1422931 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine at 20 degrees C
Number of subjects: 102
Study 1422931 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine at 5 degrees C
Number of subjects: 102
Study 6438014 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutritional support (constant infusion of a defined diet by needle catheter jejunostomy, started at 12 hours postoperatively, reaching 3000 kcal/day within 72 hours)
Number of subjects: 18
Study 6438014 — intervention group
Group type: COMPARATOR
Intervention: Conventional nutritional treatment (control group)
Number of subjects: 18
Study 31106550 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (0.2 mg/kg)
Number of subjects: 0
Study 31106550 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (0.003 mg/kg)
Number of subjects: 0
Study 28296480 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose group (HDG) - 3 classes per week for 12 weeks
Number of subjects: 30
Study 28296480 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose group (LDG) - 2 classes per week for 12 weeks
Number of subjects: 30
Study 28296480 — intervention group
Group type: COMPARATOR
Intervention: High-dose group (HDG)
Number of subjects: 30
Study 28296480 — intervention group
Group type: COMPARATOR
Intervention: Low-dose group (LDG)
Number of subjects: 30
Study 25272965 — intervention group
Group type: EXPERIMENTAL
Intervention: computer-assisted cognitive-behavioral therapy and/or medication management (ITV)
Number of subjects: 0
Study 25272965 — intervention group
Group type: COMPARATOR
Intervention: usual care (UC)
Number of subjects: 0
Study 24136890 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic model for overall survival (OS) in men treated with second-line chemotherapy
Number of subjects: 1243
Study 21962588 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS)
Number of subjects: 395
Study 21962588 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography angiography (CTA)
Number of subjects: 395
Study 21962588 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CEUS and CTA
Number of subjects: 395
Study 19220503 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 0
Study 16617400 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ICTP in patients with BC and bone metastases
Number of subjects: 97
Study 16617400 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CA 15‐3 in patients with BC and bone metastases
Number of subjects: 97
Study 16617400 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PICP in patients with BC and bone metastases
Number of subjects: 97
Study 16617400 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CEA in patients with BC and bone metastases
Number of subjects: 97
Study 16617400 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CA 15‐3, ICTP, and CEA
Number of subjects: 97
Study 16617400 — intervention group
Group type: COMPARATOR
Intervention: Bone scintigraphy
Number of subjects: 97
Study 12672684 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.00 US dollar bill
Number of subjects: 300
Study 12672684 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.00 US dollars check
Number of subjects: 300
Study 12672684 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.00 US dollar bill
Number of subjects: 300
Study 12672684 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.00 US dollars check
Number of subjects: 300
Study 12672684 — intervention group
Group type: COMPARATOR
Intervention: no incentive
Number of subjects: 300
Study 12672684 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.00 US dollar bill (sent to remaining nonresponders)
Number of subjects: 300